Ultragenyx Pharmaceutical (RARE) Other financing activities (2020 - 2024)
Ultragenyx Pharmaceutical (RARE) reported Other financing activities of $7.0 million for Q3 2024, up 580.93% on a QoQ basis from $1.0 million in Q4 2023.
Ultragenyx Pharmaceutical (RARE) has 5 years of Other financing activities data on file, last reported at $7.0 million in Q3 2024.
- Quarterly Other financing activities changed N/A year-over-year to $7.0 million in Q3 2024, while the trailing twelve-month figure through Dec 2025 was $7.0 million (changed 0.0% YoY) and the FY2024 annual result came in at $7.0 million, up 600.0% from the prior year.
- Other financing activities rose to $7.0 million in Q3 2024 per RARE's latest filing, from $1.0 million in the prior quarter.
- Across five years, Other financing activities topped out at $7.0 million in Q3 2024 and bottomed at -$147000.0 in Q3 2022.
- The 5-year median for Other financing activities is -$99500.0 (2020), against an average of $419812.5.
- The widest annual swing landed in 2021, when Other financing activities plunged 239.39%; it then surged 963.87% in 2023.
- Tracing RARE's Other financing activities over 5 years: stood at -$87000.0 in 2020, then slumped by 63.22% to -$142000.0 in 2021, then gained by 16.2% to -$119000.0 in 2022, then surged by 963.87% to $1.0 million in 2023, then jumped by 580.93% to $7.0 million in 2024.
- Per Business Quant, the three latest RARE Other financing activities figures stand at $7.0 million (Q3 2024), $1.0 million (Q4 2023), and -$56000.0 (Q2 2023).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Ultragenyx Pharmaceutical | 2.29 Bn | 1.89 Bn | 106.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 7.00 Mn |
| Sep 30, 2024 | 7.00 Mn |
| Dec 31, 2023 | 1.03 Mn |
| Dec 31, 2023 | 1.03 Mn |
| Jun 30, 2023 | -56,000.00 |
| Jun 30, 2023 | -56,000.00 |
| Mar 31, 2023 | 28,000.00 |
| Mar 31, 2023 | 28,000.00 |
| Dec 31, 2022 | -119,000.00 |
| Dec 31, 2022 | -119,000.00 |
| Sep 30, 2022 | -147,000.00 |
| Sep 30, 2022 | -147,000.00 |
| Jun 30, 2022 | -146,000.00 |
| Jun 30, 2022 | -146,000.00 |
| Mar 31, 2022 | -143,000.00 |
| Mar 31, 2022 | -143,000.00 |
| Dec 31, 2021 | -142,000.00 |
| Dec 31, 2021 | -142,000.00 |
| Sep 30, 2021 | -124,000.00 |
| Sep 30, 2021 | -124,000.00 |
| Jun 30, 2021 | -114,000.00 |
| Jun 30, 2021 | -114,000.00 |
| Mar 31, 2021 | -112,000.00 |
| Mar 31, 2021 | -112,000.00 |
| Dec 31, 2020 | -87,000.00 |
| Dec 31, 2020 | -87,000.00 |
| Sep 30, 2020 | -58,000.00 |
| Sep 30, 2020 | -58,000.00 |
| Jun 30, 2020 | -58,000.00 |
| Jun 30, 2020 | -58,000.00 |
| Mar 31, 2020 | -33,000.00 |
| Mar 31, 2020 | -33,000.00 |